Company Develop Equity Thousand Oaks 
socalTECH
OCTOBER 23, 2019
Thousand Oaks-based biotech giant Amgen said today that its CFO, David W. Meline, is planning to retire, serving as CFO through the end of 2019, but will remain at the company through the second quarter of 2020. READ MORE>>.
socalTECH
NOVEMBER 7, 2013
Thousand Oaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. According to the company, the funding came from Ally Bridge Group.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
socalTECH
SEPTEMBER 8, 2011
Thousand Oaks-based biotech giant Amgen has backed a developer of therapeutic antibodies, via its venture capital arm, Amgen Ventures. According to Seattle-based Theraclone Sciences , Amgen Ventures was one of the investors in a $10.6M, Series B extension round for the company. READ MORE>>.
socalTECH
MAY 20, 2010
Thousand Oaks-based Ceres , a developer of biofuel crop technology, and Novozymes , a developer of enzymes, said today that the two have entered into a research collaboration around cellulosic biofuel production. Ceres is working on both crops to optimize the amount of sugar which can be used to produce biofuel.
Xconomy
JULY 22, 2016
The top news in biotech this week centers around one big job opening: the head seat at Biogen, now that George Scangos has announced plans to leave the company. Who takes the gig, and the strategic direction he or she chooses for Biogen will have implications not just for the company and its employees, but the sector overall.
Xconomy
JUNE 10, 2016
The results give the company confidence it can expand its tests to screen for early cancer in high-risk people who are otherwise healthy. —More developments arrived this week in the Sarepta Therapeutics (NASDAQ: SRPT ) saga.
Expert insights. Personalized for you.
100 
Let's personalize your content